Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517595 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00517595 is a Phase 2 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 48 participants.
The verdict
NCT00517595, a Phase 2 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIB/IV non-small cell lung cancer (NSCLC). The secondary objectives are to determine the overall response rate; overall survival; chemotherapy induced toxicity profile of this combination; time to progression; and patient reported symptom burden.
Interventions
- DRUG Pemetrexed and Gemcitabine plus Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517595
The ClinicalTrials.gov registry entry for NCT00517595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed and Gemcitabine plus Bevacizumab is the first listed.
NCT00517595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517595 about?
NCT00517595 is a clinical study titled "Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC". The primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIB/IV non-small cell lung cancer (NSCLC). The secondary objectives are to determine the overall response rate; overall su...
What is the current status of trial NCT00517595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00517595?
The interventions under investigation include: Pemetrexed and Gemcitabine plus Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00517595?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.